Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial

Authors: Mori, Kristina M | JAMA Oncology | May 25, 2023 | PubMed abstract

Explore all publications

Back To Top